[12] Adverse effects [edit] Preclinical, phase I, and phase II clinical trials indicated that tirzepatide exhibits adverse effects similar to those of other established GLP-1 receptor agonists, such as dulaglutide (sold as Trulicity) and semaglutide (sold as Wegovy, Ozempic, and Rybelsus)
Stopping the medication comes with changes in food cravings and increased hunger, leading to changes in weight, with some people experiencing weight gain
This includes ongoing support for managing chronic health conditions, where the focus is on empowering individuals to lead healthier lives
Li, F., Yang, H., Duan, Y
Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: a randomized clinical trial